Work

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

Year: 2011

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2011.02.013

Authors: Lydia Usha, Michael W. Sill, Kathleen M. Darcy, Doris M. Benbrook, Jean A. Hurteau, David P. Michelin, Robert S. Mannel, Parviz Hanjani, Koen De Geest, Andrew K. Godwin

Institutions: Rush University Medical Center, Rush University, Roswell Park Comprehensive Cancer Center, University at Buffalo, State University of New York, University of Oklahoma Health Sciences Center, University of Chicago, Evanston Hospital, Munson Medical Center, Abington Memorial Hospital, University of Iowa Hospitals and Clinics, University of Kansas Medical Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1340769175, G1934877167, G1950154987, Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer, GYNECOLOGIC ONCOLOGY GROUP STATISTICAL AND DATA CENTER, Gynecologic Oncology Group, G5377380291, G70736214

OpenAlex ID: W1975479767

FWCI: 9.673

Cites: 56

Cited by: 50

Related to: 10